GreenLight Biosciences (GRNAW)
GreenLight Biosciences Statistics
Share Statistics
GreenLight Biosciences has 0 shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 0 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.93 and the forward PE ratio is null. GreenLight Biosciences's PEG ratio is -0.03.
| PE Ratio | -0.93 |
| Forward PE | n/a |
| PS Ratio | 24.39 |
| Forward PS | null |
| PB Ratio | 3.24 |
| P/FCF Ratio | -0.95 |
| PEG Ratio | -0.03 |
Enterprise Valuation
GreenLight Biosciences has an Enterprise Value (EV) of 168.12M.
| EV / Sales | 26.33 |
| EV / EBITDA | -1.09 |
| EV / EBIT | -1.23 |
| EV / FCF | -1.03 |
Financial Position
The company has a current ratio of 2.01, with a Debt / Equity ratio of 1.67.
| Current Ratio | 2.01 |
| Quick Ratio | 2.01 |
| Debt / Equity | 1.67 |
| Debt / EBITDA | -0.52 |
| Debt / FCF | -0.49 |
| Interest Coverage | -39.76 |
Financial Efficiency
Return on Equity is -347.58% and Return on Invested Capital is -128.36%.
| Return on Equity | -347.58% |
| Return on Assets | -112.42% |
| Return on Invested Capital | -128.36% |
| Revenue Per Employee | $22.8K |
| Profits Per Employee | $-596.63K |
| Employee Count | 280 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.09M |
| Effective Tax Rate | -0.66% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so GreenLight Biosciences's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.1 |
| Relative Strength Index (RSI) | 54.41 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, GreenLight Biosciences had revenue of 6.38M and earned -167.06M in profits. Earnings per share was -1.27.
| Revenue | 6.38M |
| Gross Profit | 6.38M |
| Operating Income | -163.92M |
| Net Income | -167.06M |
| EBITDA | -153.99M |
| EBIT | -161.84M |
| Earnings Per Share (EPS) | -1.27 |
Balance Sheet
The company has 68.1M in cash and 80.48M in debt, giving a net cash position of -12.38M.
| Cash & Cash Equivalents | 68.1M |
| Total Debt | 80.48M |
| Net Cash | -12.38M |
| Retained Earnings | -420.64M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -136.73M and capital expenditures -26.55M, giving a free cash flow of -163.28M.
| Operating Cash Flow | -136.73M |
| Capital Expenditures | -26.55M |
| Free Cash Flow | -163.28M |
| FCF Per Share | -1.24 |
Margins
Gross margin is 100%, with operating and profit margins of -2567.65% and -2616.78%.
| Gross Margin | 100% |
| Operating Margin | -2567.65% |
| Pretax Margin | -2599.67% |
| Profit Margin | -2616.78% |
| EBITDA Margin | -2412.11% |
| EBIT Margin | -2567.65% |
| FCF Margin | -2557.61% |
Dividends & Yields
GRNAW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -107.27% |
| FCF Yield | -104.85% |
Analyst Forecast
Currently there are no analyst rating for GRNAW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |